| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194441 Gramnegative and grampositive bacteria |
| 02/27/2001 | US6194430 Viral treatment |
| 02/27/2001 | US6194429 Purification with a hydrophobic resin |
| 02/27/2001 | US6194426 5,6,7,8 tetrahydroindolizines derivatives |
| 02/27/2001 | US6194425 Viricides, antitumor agents |
| 02/27/2001 | US6194413 Hemoregulatory compounds |
| 02/27/2001 | US6194398 Phosphonate nucleotide compound |
| 02/27/2001 | US6194391 Cs-87 (title compound) induces a transient mutation in hiv-1 at the 70th codon of the reverse transcriptase region of the virus; administering to a human in need of therapy with a drug that induces a mutation in hiv-1 at another location |
| 02/27/2001 | US6194390 Administering hydroxyurea and a 2'-fluoropurine-dideoxy-nucleoside selected from the group of 2'-fluoro-2',3'-dide-oxyadenosine,-dideoxyinosine, and -dideoxyguanosine with a carrier or excipient; viricides; retroviruses; plant viruses |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194387 6-O-aklyl erythromycin B oxime |
| 02/27/2001 | US6194383 Homologous cyclic amino-acid sequences having different fatty acid residues synthesized by actinoplanes sp.; peptide antibiotics, lipopeptides a 1437, a-m, effective against grampositive bacteria and glycopeptide-resistant strains |
| 02/27/2001 | US6194212 Increasing gene expression by transducing eukaryotic cells with retrovirus vector having heterologous gene linked to regulatory sequence and scaffold attachment region of human interferon-beta gene, allowing cells to rest and express gene |
| 02/27/2001 | US6194207 Methods for the selective expansion of lymphocytes by in vitro cultivation |
| 02/27/2001 | US6194205 Multistep process using conditionally immortalized antigen-presenting cells which are engineered to express antigen of interest, adding leukocytic cells, and culturing mixture to activate the t cells |
| 02/27/2001 | US6194161 Staphylococcus aureus antigen |
| 02/27/2001 | US6194142 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2, and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses |
| 02/27/2001 | US6194140 HCV NS3 protein fragments having helicase activity and improved solubility |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6193996 Device for the transdermal delivery of diclofenac |
| 02/27/2001 | US6193984 Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins |
| 02/27/2001 | US6193983 Equine herpesvirus glycoproteins |
| 02/27/2001 | US6193982 Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
| 02/27/2001 | US6193981 Methods and compositions for impairing multiplication of HIV-1 |
| 02/27/2001 | US6193969 Preventing, ameliorating, or treating septic shock or its symptoms by administering igg (immunoglobulin g) fab fragments reactive towards tnf.alpha.(tumor nercosis factor), wherein igg fab fragments are derived from polyclonal igg |
| 02/27/2001 | US6193966 Administering bispecific protein or peptide molecule, comprising a first binding determinate which binds to fc.alpha.receptor without being blocked by immunoglobulin a and second binding determinant which binds to target antigen |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6192887 Comprising compound selected from sodium dodecyl sulfate, lithium dodecyl sulfate, lauric acid or a pharmaceutically acceptable salt thereof in a sufficient amount to attain a virucidal effect against a non-enveloped virus |
| 02/27/2001 | CA2190952C Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection |
| 02/27/2001 | CA2102454C Erythromycin derivatives, process for the preparation thereof, and use thereof as medicaments |
| 02/27/2001 | CA2025598C Chimaeric hepadnavirus core antigen proteins |
| 02/22/2001 | WO2001012804A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 02/22/2001 | WO2001012797A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012787A2 Chimeric dna/rna ribozymes containing propanediol |
| 02/22/2001 | WO2001012786A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012668A1 Cathelicidin-derived peptides with broad spectrum antimicrobial activity |
| 02/22/2001 | WO2001012652A1 fabF |
| 02/22/2001 | WO2001012644A1 Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptases and viruses |
| 02/22/2001 | WO2001012643A1 Antibiotic caprazamycins and process for producing the same |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012605A1 6,7-disubstituted-5,8-quinolinedione derivatives as an antifungal agent |
| 02/22/2001 | WO2001012603A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012264A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012228A2 Compositions for treating viral infections, and methods therefor |
| 02/22/2001 | WO2001012224A1 Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
| 02/22/2001 | WO2001012223A2 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 02/22/2001 | WO2001012220A1 Non-immunosuppressant hiv tat |
| 02/22/2001 | WO2001012219A1 Pneumococcal vaccines |
| 02/22/2001 | WO2001012215A2 Protective antigen of epstein barr virus |
| 02/22/2001 | WO2001012214A2 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012182A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | WO2001012181A1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 02/22/2001 | WO2001012164A1 Oral form of administration containing probiotic micro-organisms |
| 02/22/2001 | WO2001012162A1 Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001012127A2 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 02/22/2001 | WO2001011971A1 Natural, anti-bacterial, anti-inflammation, anti-virus, anti-herpes cream |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000078773A3 Process for preparing 6-o-alkenyl-substituted erythromycin deriv atives |
| 02/22/2001 | WO2000077246A3 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000074677A3 Improved pharmaceutical formulations |
| 02/22/2001 | WO2000071737A3 Improved retroviral production by inhibition of the enveloppe cell receptor |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000069470A3 Improved cellular uptake of bioactive agents |
| 02/22/2001 | WO2000064936A3 PEPTIDE HOMODIMERS AND PEPTIDE HETERODIMERS, DERIVED FROM INTERFERON α2 |
| 02/22/2001 | WO2000063385A3 Nucleic acid immunization |
| 02/22/2001 | WO2000061761A3 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| 02/22/2001 | WO2000057904B1 Attenuated dengue-3 virus vaccine |
| 02/22/2001 | WO1999049883A3 Oxidized thymosin beta 4 |
| 02/22/2001 | WO1999047553A3 Bacterial yeal family members as targets for antimicrobial drug design |
| 02/22/2001 | DE19939653A1 Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung Using CD28 specific monoclonal antibodies for the preparation of a pharmaceutical composition |
| 02/22/2001 | DE19939578A1 New nucleic acid encoding hemocyanin, useful for gene therapy of tumors and for recombinant production of fusion proteins for vaccination |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | DE19937361A1 Orale Darreichungsform The oral dosage form |
| 02/22/2001 | CA2784789A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |